Lonza signed a worldwide, exclusive licensing and supply agreement with California Stem Cell focused on the development of novel pluripotent stem cell products for research. The partnership will combine CSCâs methods for the scalable production of multiple cell types from human pluripotent stem cells (hPSCs) with Lonzaâs expertise in primary cells and its marketing muscle.
âThis partnership will address the evolving needs of the research community by making broadly available high-purity, human pluripotent stem cell-derived cells and related media products wordwide,â comments Hans Keirstead, chairman of CSCâs scientific advisory board.
The firms envisage that the first products to be marketed under the agreement will include NeuroPlateâ¢ hPSC-derived neural progenitors and MotorPlateâ¢ hPSC-derived motor neuron progenitors. Launch of the products with associated culture media is anticipated during 2010. Additional products are also planned for launch this year, and Lonza will begin to manufacture and distribute CSCâs media portfolio.
The collaboration marks Lonzaâs entry in the hPSC market, the firm points out, and the CSC portfolio will complement its own CloneticsÂ® and PoieticsÂ® brands of primary stem cells and optimized media. âCalifornia Stem Cell is one of the few companies that is able to produce cells derived from human pluripotent stem cells in the quantities needed to support our customersâ research programs worldwide,â remarks Heun van der Heide, Lonzaâs head of research solutions.